Pharma Dispatch 20 January 2023 New Zealand Approval for Specialised Therapeutics’ Cancer Therapy Specialised Therapeutics Asia has announced that its therapy to treat rare gastrointestinal stromal tumours, QINLOCK (ripretinib), has been approved for use in New Zealand and will now be considered for funding by PHARMAC. The regulator, Medsafe, has approved QINLOCK for
